DOI: https://doi.org/10.26641/2307-5279.22.4.2018.152473

Combined hormonal and radionuclide-medication therapy of prostate cancer

V.M. Grygorenko, O.V. Scherbina, S.S. Volkov, R.O. Danylets, M.V. Vikarchuk

Abstract


Aim. To improve the quality of providing specialized care to patients with prostate cancer by evaluation the effectiveness of the long-term results of different regimes of hormonal and radionuclide-medication therapy.

Matherials and methods. Was studied effectiveness of hormonal therapy in 246 patients with localized and advanced prostate cancer who received hormonal therapy under different regimes from 1997 to 2010.

Results. During treatment in all groups there was a decrease in the intensity of complaints, improvement of uroflowmetry, reduction of prostate volume and reduction of PSA without a significant difference between the indicated parameters among the groups. Indicators of general and cancers-specific survival and survival, depending on the presence of metastases between the groups, also did not differ statistically (p>0.05). In the treatment of patients with multiple bone metastasis was achieved long pain reduction (up to 10–12 months), with improvement of quality of life, motor activity, absence of pathological fractures and other complications.

Conclusions. Treatment in the LDEAT mode can achieve a significant therapeutic effect in a short time with less pronounced side effects. The dose reduction of flutamide does not reduce the overall and cancers-specific survival rates and improves the tolerability of treatment. In patients with multiple bone metastasis it was possible to achieve a significant therapeutic effect by the appointment of combined hormonal and radionuclide-medication therapy.

Keywords


cancer; hormone therapy; steroid antiandrogen; nonsteroidal antiandrogen; LH-RG analogue; estrogen; radiopharmaceutical; bisphosphonates

References


Arnold, M., et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer, 2015; 51: 1164.

United States Cancer Statistics: 1999–2006 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2010.

Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the PSA-ERA // Int J Cancer – 2001 - 92(6) – P. 893–898.

Федоренко ЗП, Гулак ЛО, Михайлович ЮЙ. та ін. Рак в Україні, 2015-2016. Бюлетень національного канцер-реєстру України. – Київ, 2017:54-55.

Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250–1261

Wiegel T, Bottke D, Steiner U. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Cli. Oncol.2009;27:2924–2930.

Dorff TB, Flaig TW, Tangen CM. et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol.2011;29:2040–2045.

Daly T, Hickey BE, Lehman M, et al. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev. 2011:CD007234.

Briganti A, Karnes RJ, Da Pozzo LF, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pNю prostate cancer: results of a matched analysis. Eur Urol. 2011;59:832–840.